Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

New data shows GSK-Vir drug works against all Omicron mutations

12/07/2021 | 02:26am EST

Dec 7 (Reuters) - Britain's GSK released new data on Tuesday from early-stage studies, citing that its antibody-based COVID-19 therapy with U.S. partner Vir is effective against all mutations of the new Omicron coronavirus variant.

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement https://www.gsk.com/en-gb/media/press-releases/sotrovimab-retains-activity. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry Jacob-Phillips)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -1.97% 1633.6 Delayed Quote.3.72%
VIR BIOTECHNOLOGY, INC. -2.53% 33.14 Delayed Quote.-18.80%
All news about VIR BIOTECHNOLOGY, INC.
01/14WHO recommendation on Merck's oral pill likely in early February
RE
01/13GSK-Vir, Eli Lilly's COVID-19 Treatments Recommended by WHO
MT
01/13WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool
RE
01/13GSK, Vir Biotechnology Seek US FDA's Nod to Amend Emergency Use Authorization for COVID..
MT
01/13Vir Biotechnology to Get Investment, Grant From Gates Foundation for HIV, Malaria Resea..
MT
01/13GlaxoSmithKline, Vir Biotechnology Apply to FDA to Amend EUA for COVID-19 Treatment
MT
01/13Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure ..
GL
01/13Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure ..
GL
01/13GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Adm..
AQ
01/13GlaxoSmithKline Secures $945.1 Million US Army Contract Modification
MT
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 696 M - -
Net income 2021 233 M - -
Net cash 2021 912 M - -
P/E ratio 2021 19,5x
Yield 2021 -
Capitalization 4 337 M 4 337 M -
EV / Sales 2021 4,92x
EV / Sales 2022 2,33x
Nbr of Employees 395
Free-Float -
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 34,00 $
Average target price 91,43 $
Spread / Average Target 169%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.-18.80%4 450
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923